Colon Cancer and the Immune System: the Role of Tumor Invading T Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2006 Dec 5

PMID 17143936

Citations 46

Authors

Maximilian Waldner

Carl-C Schimanski

Markus-F Neurath

Affiliations

Soon will be listed here.

Abstract

Colon cancer is still one of the leading causes of cancer death worldwide. Although the host immune system has been shown to react against tumor cells, mainly through tumor infiltrating lymphocytes and NK cells, tumor cells may utilize different ways to escape anti-tumor immune response. Tumor infiltration of CD8+ and CD4+ (T-bet+) effector T cells has been attributed to a beneficial outcome, and the enhancement of T cell activation through T cell receptor stimulation and co-stimulatory signals provides promising strategies for immunotherapy of colon cancer. Growing evidence supports a role for the Fas/FasL system in tumor immunology, although the mechanisms and consequences of FasL activation in colon cancer are not completely understood. In animal models, depletion of regulatory T cells (CD4+ CD25+ T cells) can enhance the anti-tumor immune response under certain conditions. Taken together, recent insights in the immune reaction against colon carcinoma have provided new approaches to immunotherapy, although much remains to be learned about the exact mechanisms.

Citing Articles

Prognostic cellular senescence-related lncRNAs patterns to predict clinical outcome and immune response in colon cancer.

Cao L, Chen F, Xu L, Zeng J, Wang Y, Zhang S Front Immunol. 2024; 15:1450135.

PMID: 39355236 PMC: 11443174. DOI: 10.3389/fimmu.2024.1450135.

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.

Nikolouzakis T, Chrysos E, Docea A, Fragkiadaki P, Souglakos J, Tsiaoussis J Cancers (Basel). 2024; 16(11).

PMID: 38893120 PMC: 11171065. DOI: 10.3390/cancers16111995.

Isolation and high-dimensional flow cytometric analysis of tumor-infiltrating leukocytes in a mouse model of colorectal cancer.

Eich C, Vogt J, Langst V, Clausen B, Hovelmeyer N Front Immunol. 2024; 15:1295863.

PMID: 38500875 PMC: 10944955. DOI: 10.3389/fimmu.2024.1295863.

Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer.

Xu X, Zhang X, Kou R, Liu Y, Chen S, Li Z J Cancer Res Clin Oncol. 2024; 150(2):31.

PMID: 38270646 PMC: 10811099. DOI: 10.1007/s00432-023-05573-6.

Current perspective on biological properties of plasmacytoid dendritic cells and dysfunction in gut.

Guo X, He C, Xin S, Gao H, Wang B, Liu X Immun Inflamm Dis. 2023; 11(9):e1005.

PMID: 37773693 PMC: 10510335. DOI: 10.1002/iid3.1005.

References

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25):2654-66. DOI: 10.1056/NEJMoa051424. View

Guy-Grand D, Vassalli P . Gut intraepithelial lymphocyte development. Curr Opin Immunol. 2002; 14(2):255-9. DOI: 10.1016/s0952-7915(02)00330-8. View

Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M . Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun. 2004; 4:14. View

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Erdman S, Sohn J, Rao V, Nambiar P, Ge Z, Fox J . CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 2005; 65(10):3998-4004. DOI: 10.1158/0008-5472.CAN-04-3104. View

Donda A, Cesson V, Mach J, Corradin G, Primus F, Robert B . In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts. Cancer Immun. 2003; 3:11. View

Zhang W, Ding E, Wang Q, Zhu D, He J, Li Y . Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol. 2005; 11(23):3632-5. PMC: 4315977. DOI: 10.3748/wjg.v11.i23.3632. View

Wolf D, Wolf A, Rumpold H, Fiegl H, Zeimet A, Muller-Holzner E . The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11(23):8326-31. DOI: 10.1158/1078-0432.CCR-05-1244. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

10.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H . CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58(16):3491-4. View

11.

Melief C . Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur J Immunol. 2003; 33(10):2645-54. DOI: 10.1002/eji.200324341. View

12.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

13.

Rupnarain C, Dlamini Z, Naicker S, Bhoola K . Colon cancer: genomics and apoptotic events. Biol Chem. 2004; 385(6):449-64. DOI: 10.1515/BC.2004.053. View

14.

Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E . High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999; 154(6):1805-13. PMC: 1866613. DOI: 10.1016/S0002-9440(10)65436-3. View

15.

Suzuki H, Graziano D, McKolanis J, Finn O . T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res. 2005; 11(4):1521-6. DOI: 10.1158/1078-0432.CCR-04-0538. View

16.

Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T . Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 2003; 63(4):854-8. View

17.

Norazmi M, Hohmann A, Skinner J, Bradley J . Expression of MHC class I and class II antigens in colonic carcinomas. Pathology. 1989; 21(4):248-53. DOI: 10.3109/00313028909061068. View

18.

Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J . Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer. 2006; 118(12):3054-61. DOI: 10.1002/ijc.21688. View

19.

Xu D, Sauter B, Huang T, Meseck M, Woo S, Chen S . The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther. 2005; 12(20):1526-33. DOI: 10.1038/sj.gt.3302556. View

20.

Fujihashi K, Yamamoto M, McGhee J, Beagley K, Kiyono H . Function of alpha beta TCR+ intestinal intraepithelial lymphocytes: Th1- and Th2-type cytokine production by CD4+CD8- and CD4+CD8+ T cells for helper activity. Int Immunol. 1993; 5(11):1473-81. DOI: 10.1093/intimm/5.11.1473. View